Evommune (EVMN) Capital Leases (2024 - 2026)

Evommune's (EVMN) quarterly Capital Leases came in at $529000.0 in Q1 2026, up 192.27% on a QoQ basis from $181000.0 in Q4 2025.

Evommune (EVMN) Capital Leases (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Capital Leases data on file, last reported at $529000.0 in Q1 2026.

On a quarterly basis, Capital Leases changed N/A year-over-year to $529000.0 in Q1 2026; TTM through Mar 2026 was $529000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $181000.0, down 66.17% from the prior year.
Capital Leases for Q1 2026 stood at $529000.0, up from $181000.0 in the prior quarter.
Over the last five years, Capital Leases for EVMN reached as high as $535000.0 in Q4 2024 and fell as low as $181000.0 in Q4 2025.
Historically, Capital Leases has averaged $415000.0 across 3 years, with a median of $529000.0 in 2026.
On a YoY basis, Capital Leases climbed as much as 66.17% in 2025 and fell as far as 66.17% in 2025.
Year by year, Capital Leases stood at $535000.0 in 2024, then sank by 66.17% to $181000.0 in 2025, then surged by 192.27% to $529000.0 in 2026.
Per Business Quant data, the three most recent Capital Leases figures were $529000.0 in Q1 2026, $181000.0 in Q4 2025, and $535000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Evommune	381.48 Mn	170.02 Mn	-

Download Data